Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)

Vicki A Morrison; Sin Ho Jung; Jeffrey Johnson; Ann Lacasce; Kristie A. Blum; Nancy L. Bartlett; Brandelyn N. Pitcher; Bruce D. Cheson

doi:10.3109/10428194.2014.938333

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)

Vicki A Morrison, Sin Ho Jung, Jeffrey Johnson, Ann Lacasce, Kristie A. Blum, Nancy L. Bartlett, Brandelyn N. Pitcher, Bruce D. Cheson

Medicine - Veteran's Administration Medical Center

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Abstract Cancer and Leukemia Group B designed a phase II trial of lenalidomide + bortezomib for relapsed/refractory mantle cell lymphoma (MCL). Induction therapy was lenalidomide (days 1-14) plus bortezomib (days 1/4/8/11), every 21 days for eight cycles. Complete/partial responders (CR, PR) received maintenance lenalidomide (days 1-14) and bortezomib (days 1/8), every 21 days. Primary endpoint was overall response rate; secondary endpoints were CR rate, progression-free (PFS), event-free (EFS) and overall survival (OS). Fifty-three eligible patients, median age 67 years, were accrued. Median number of cycles received was 4 (range, 1-82). Median followup was 46 (range, 12-67) months. Best response was CR 15%, PR 25%. 5/8 CR, and 4/13 PR patients received maintenance. Six CR and one PR patient remain in remission (median, 3.2 years). Thirty-three (62%) patients have died. One-year PFS, EFS and OS are 40%, 25% and 68%, respectively. This combination will not be pursued further.

Original language	English (US)
Pages (from-to)	958-964
Number of pages	7
Journal	Leukemia and Lymphoma
Volume	56
Issue number	4
DOIs	https://doi.org/10.3109/10428194.2014.938333
State	Published - Apr 1 2015

Bibliographical note

Funding Information:
The research for CALGB 50501 (Alliance) was supported, in part, by grants from the National Cancer Institute (CA31946) to the Alliance for Clinical Trials in Oncology (Monica M. Bertagnolli, MD, Chair) and to the Alliance Statistics and Data Center (Daniel J. Sargent, PhD, CA33601). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.

Funding Information:
The following Alliance/CALGB institutions participated in this study: Christiana Care Health Services, Inc. CCOP, Wilmington, DE, Stephen Grubbs, MD, supported by CA45418 Dana-Farber Cancer Institute, Boston, MA, Harold J. Burstein, MD, PhD, supported by CA32291 Dartmouth Medical School-Norris Cotton Cancer Center, Lebanon, NH, Konstantin Dragnev, MD, supported by CA04326 Georgetown University Medical Center, Washington, DC, Bruce Cheson, MD, supported by CA77597 Grand Rapids Clinical Oncology Program, Grand Rapids, MI, Martin J. Bury, MD Massachusetts General Hospital, Boston, MA, Jeffrey W. Clark, MD, supported by CA32291 Southeast Cancer Control Consortium, Inc. CCOP, Goldsboro, NC, James N. Atkins, MD, supported by CA45808

Publisher Copyright:
© 2014 Informa UK, Ltd.

Keywords

Bortezomib
Lenalidomide
Mantle cell lymphoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.3109/10428194.2014.938333

Find It

Find It at U of M Libraries

Cite this

@article{bb85f0143c094416becde46c51dc235f,

title = "Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)",

abstract = "Abstract Cancer and Leukemia Group B designed a phase II trial of lenalidomide + bortezomib for relapsed/refractory mantle cell lymphoma (MCL). Induction therapy was lenalidomide (days 1-14) plus bortezomib (days 1/4/8/11), every 21 days for eight cycles. Complete/partial responders (CR, PR) received maintenance lenalidomide (days 1-14) and bortezomib (days 1/8), every 21 days. Primary endpoint was overall response rate; secondary endpoints were CR rate, progression-free (PFS), event-free (EFS) and overall survival (OS). Fifty-three eligible patients, median age 67 years, were accrued. Median number of cycles received was 4 (range, 1-82). Median followup was 46 (range, 12-67) months. Best response was CR 15%, PR 25%. 5/8 CR, and 4/13 PR patients received maintenance. Six CR and one PR patient remain in remission (median, 3.2 years). Thirty-three (62%) patients have died. One-year PFS, EFS and OS are 40%, 25% and 68%, respectively. This combination will not be pursued further.",

keywords = "Bortezomib, Lenalidomide, Mantle cell lymphoma",

author = "Morrison, {Vicki A} and Jung, {Sin Ho} and Jeffrey Johnson and Ann Lacasce and Blum, {Kristie A.} and Bartlett, {Nancy L.} and Pitcher, {Brandelyn N.} and Cheson, {Bruce D.}",

note = "Funding Information: The research for CALGB 50501 (Alliance) was supported, in part, by grants from the National Cancer Institute (CA31946) to the Alliance for Clinical Trials in Oncology (Monica M. Bertagnolli, MD, Chair) and to the Alliance Statistics and Data Center (Daniel J. Sargent, PhD, CA33601). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. Funding Information: The following Alliance/CALGB institutions participated in this study: Christiana Care Health Services, Inc. CCOP, Wilmington, DE, Stephen Grubbs, MD, supported by CA45418 Dana-Farber Cancer Institute, Boston, MA, Harold J. Burstein, MD, PhD, supported by CA32291 Dartmouth Medical School-Norris Cotton Cancer Center, Lebanon, NH, Konstantin Dragnev, MD, supported by CA04326 Georgetown University Medical Center, Washington, DC, Bruce Cheson, MD, supported by CA77597 Grand Rapids Clinical Oncology Program, Grand Rapids, MI, Martin J. Bury, MD Massachusetts General Hospital, Boston, MA, Jeffrey W. Clark, MD, supported by CA32291 Southeast Cancer Control Consortium, Inc. CCOP, Goldsboro, NC, James N. Atkins, MD, supported by CA45808 Publisher Copyright: {\textcopyright} 2014 Informa UK, Ltd.",

year = "2015",

month = apr,

day = "1",

doi = "10.3109/10428194.2014.938333",

language = "English (US)",

volume = "56",

pages = "958--964",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma

T2 - Final results of a phase II trial (CALGB 50501)

AU - Morrison, Vicki A

AU - Jung, Sin Ho

AU - Johnson, Jeffrey

AU - Lacasce, Ann

AU - Blum, Kristie A.

AU - Bartlett, Nancy L.

AU - Pitcher, Brandelyn N.

AU - Cheson, Bruce D.

N1 - Funding Information: The research for CALGB 50501 (Alliance) was supported, in part, by grants from the National Cancer Institute (CA31946) to the Alliance for Clinical Trials in Oncology (Monica M. Bertagnolli, MD, Chair) and to the Alliance Statistics and Data Center (Daniel J. Sargent, PhD, CA33601). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. Funding Information: The following Alliance/CALGB institutions participated in this study: Christiana Care Health Services, Inc. CCOP, Wilmington, DE, Stephen Grubbs, MD, supported by CA45418 Dana-Farber Cancer Institute, Boston, MA, Harold J. Burstein, MD, PhD, supported by CA32291 Dartmouth Medical School-Norris Cotton Cancer Center, Lebanon, NH, Konstantin Dragnev, MD, supported by CA04326 Georgetown University Medical Center, Washington, DC, Bruce Cheson, MD, supported by CA77597 Grand Rapids Clinical Oncology Program, Grand Rapids, MI, Martin J. Bury, MD Massachusetts General Hospital, Boston, MA, Jeffrey W. Clark, MD, supported by CA32291 Southeast Cancer Control Consortium, Inc. CCOP, Goldsboro, NC, James N. Atkins, MD, supported by CA45808 Publisher Copyright: © 2014 Informa UK, Ltd.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Abstract Cancer and Leukemia Group B designed a phase II trial of lenalidomide + bortezomib for relapsed/refractory mantle cell lymphoma (MCL). Induction therapy was lenalidomide (days 1-14) plus bortezomib (days 1/4/8/11), every 21 days for eight cycles. Complete/partial responders (CR, PR) received maintenance lenalidomide (days 1-14) and bortezomib (days 1/8), every 21 days. Primary endpoint was overall response rate; secondary endpoints were CR rate, progression-free (PFS), event-free (EFS) and overall survival (OS). Fifty-three eligible patients, median age 67 years, were accrued. Median number of cycles received was 4 (range, 1-82). Median followup was 46 (range, 12-67) months. Best response was CR 15%, PR 25%. 5/8 CR, and 4/13 PR patients received maintenance. Six CR and one PR patient remain in remission (median, 3.2 years). Thirty-three (62%) patients have died. One-year PFS, EFS and OS are 40%, 25% and 68%, respectively. This combination will not be pursued further.

AB - Abstract Cancer and Leukemia Group B designed a phase II trial of lenalidomide + bortezomib for relapsed/refractory mantle cell lymphoma (MCL). Induction therapy was lenalidomide (days 1-14) plus bortezomib (days 1/4/8/11), every 21 days for eight cycles. Complete/partial responders (CR, PR) received maintenance lenalidomide (days 1-14) and bortezomib (days 1/8), every 21 days. Primary endpoint was overall response rate; secondary endpoints were CR rate, progression-free (PFS), event-free (EFS) and overall survival (OS). Fifty-three eligible patients, median age 67 years, were accrued. Median number of cycles received was 4 (range, 1-82). Median followup was 46 (range, 12-67) months. Best response was CR 15%, PR 25%. 5/8 CR, and 4/13 PR patients received maintenance. Six CR and one PR patient remain in remission (median, 3.2 years). Thirty-three (62%) patients have died. One-year PFS, EFS and OS are 40%, 25% and 68%, respectively. This combination will not be pursued further.

KW - Bortezomib

KW - Lenalidomide

KW - Mantle cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84929119124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929119124&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.938333

DO - 10.3109/10428194.2014.938333

M3 - Article

C2 - 24996441

AN - SCOPUS:84929119124

SN - 1042-8194

VL - 56

SP - 958

EP - 964

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 4

ER -

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this